Search

Search Results

• 

  Factor XI inhibitors in adjunct to antiplatelet therapy: the ultimate dual-pathway inhibition?

  Mattia Galli, C. Michael Gibson, Dominick J. Angiolillo

  03-08-2023

  https://doi.org/10.4081/btvb.2023.90

  2151

  PDF: 805
• 

  Influence of emicizumab on protein C-mediated clotting regulation

  Federica Mancazzo, Antonia Vitulli, Lavinia Dirienzo, Concetta T. Ammollo, Fabrizio Semeraro, Mario Colucci

  25-10-2023

  https://doi.org/10.4081/btvb.2023.89

  2643

  PDF: 435

  Supplementary Material: 135

• PO77 | The clinical awareness of mixing test interpretation in the era of complex reporting algorithm: do we forget the origins? A. Fassina, L. De Valentin, S. Luzi, R. Turrini, A. Antico, L. Zardo | Laboratorio Analisi Castelfranco Veneto, ULSS Marca Trevigiana, Italy

  22-10-2025

  https://doi.org/10.4081/btvb.2025.346

  623

  PDF: 15

• CO-55 | DEVELOPMENT OF ENGINEERED LONG-ACTING BYPASSING FX VIA ALBUMIN FUSION FOR HEMOPHILIA WITH INHIBITORS A. Martucci¹, R. Tarantino¹, K.H. Aaen², M. Pinotti¹, J.T. Andersen², A. Branchini¹ | ¹Department of Life Sciences and Biotechnology, University of Ferrara, Ferrara, Italy; ²Institute of Clinical Medicine, Department of Pharmacology, University of Oslo, Norway

  Alessandro Martucci

  14-10-2026

  https://doi.org/10.4081/btvb.2026.665

  9

  PDF: 2

• CO-32 | TRAUMA MANAGEMENT IN SEVERE HEMOPHILIA A: A CASE REPORT J. Di Paolo, R. Malizia, M. Luongo, P. Massaro, M. Di Mascio, S. Verna | Immunohematology Service, ASL 02 Abruzzo, Chieti, Italy

  Josephine Di Paolo

  14-10-2026

  https://doi.org/10.4081/btvb.2026.642

  8

  PDF: 1
• 

  PO53 | PHASE 3 TRIAL EVALUATING THE EFFICACY AND SAFETY OF REGN7508^CAT FOR PRIMARY PROPHYLAXIS OF CANCER-ASSOCIATED THROMBOSIS FOR PARTICIPANTS WITH SOLID TUMORS UNDERGOING CANCER TREATMENT (ROXI-CAT-I) J. Zwicker¹, M. P. O’Brien², M. Carrier³, J. Connors⁴, A. Falanga⁵, A. Manzano⁶, R. Mcbane⁷, Y.Y. Janjigian¹, G. O’Kane⁸, M. Onisko², J. Kaplan², A.P. Kithcart², D.E. Gutstein², A. Khorana⁹, M. F. Walsh² | ¹Memorial Sloan Kettering Cancer Center, New York, USA; ²Regeneron Pharmaceuticals, Inc. , Tarrytown, NY, USA; ³University of Ottawa, Ottawa, ON, Canada; ⁴Harvard Medical School, Boston, MA, USA; ⁵Hospital Papa Giovanni XXIII, Bergamo, Italy; ⁶Hospital Universitario 12 de Octubre, Madrid, Spain; ⁷Mayo Clinic, Rochester, MN, USA; ⁸St. Vincent's University Hospital and School of Medicine, University College Dublin, Dublin, Ireland; ⁹James P. Wilmot Cancer Center and the Department of Medicine, University of Rochester, Rochester, NY, USA

  ICTHIC 2026

  16-04-2026

  https://doi.org/10.4081/btvb.2026.545

  488

  PDF: 121